Description

Cellid, a South Korean firm established in 2006, specializes in creating immunotherapeutic vaccines designed to combat various cancers and infectious ailments. Their pipeline includes BVAC-C, which targets cervical, head and neck, anal, and genital cancers linked to the human papillomavirus (HPV) antigen. They are also advancing BVAC-B for gastric, ovarian, lung, and pancreatic cancers, focusing on the HER-2/neu antigen, and BVAC-P, intended for prostate, urinary tract, and brain cancers by leveraging PAP/PSMA antigens. Furthermore, Cellid is working on BVAC-M for melanoma and other cancers, utilizing GP100/MAGE-A3 antigens, alongside BVAC-Neo, a personalized immunotherapeutic vaccine solution.